Pharmacological inhibition of xCT has been extensively explored using small-molecule inhibitors such as SAS, erastin, and sorafenib, all of which reduce cystine uptake and disrupt intracellular redox homeostasis, sensitizing tumor cells to oxidative stress and ferroptotic cell death in preclinical models [117,193,194]. This evidence concerns the gene SLC7A11 and neoplasm.